Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $8.29 Average PT from Brokerages

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have earned a consensus recommendation of “Buy” from the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $8.2857.

TSHA has been the topic of several recent analyst reports. Chardan Capital increased their price objective on shares of Taysha Gene Therapies from $9.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, August 12th. Wells Fargo & Company raised their price target on shares of Taysha Gene Therapies from $7.50 to $8.00 and gave the company an “overweight” rating in a research note on Wednesday, August 13th. Needham & Company LLC reiterated a “buy” rating and set a $8.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, July 1st. Canaccord Genuity Group increased their target price on Taysha Gene Therapies from $9.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, June 3rd. Finally, Bank of America started coverage on Taysha Gene Therapies in a research note on Friday, July 11th. They issued a “buy” rating and a $8.00 price target on the stock.

Insiders Place Their Bets

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $3.23, for a total value of $646,000.00. Following the completion of the sale, the insider directly owned 1,006,439 shares of the company’s stock, valued at $3,250,797.97. This trade represents a 16.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 3.78% of the company’s stock.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of institutional investors have recently bought and sold shares of TSHA. Nuveen LLC acquired a new position in shares of Taysha Gene Therapies in the 1st quarter valued at $760,000. BNP Paribas Financial Markets acquired a new position in Taysha Gene Therapies during the fourth quarter worth $41,000. Millennium Management LLC acquired a new stake in shares of Taysha Gene Therapies in the fourth quarter valued at $262,000. Octagon Capital Advisors LP raised its holdings in shares of Taysha Gene Therapies by 2.4% in the 1st quarter. Octagon Capital Advisors LP now owns 10,700,000 shares of the company’s stock valued at $14,873,000 after buying an additional 250,000 shares during the period. Finally, Ameriprise Financial Inc. acquired a new stake in shares of Taysha Gene Therapies during the fourth quarter worth about $40,000. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies Price Performance

Shares of NASDAQ:TSHA opened at $3.16 on Friday. Taysha Gene Therapies has a twelve month low of $1.05 and a twelve month high of $3.40. The company has a current ratio of 12.48, a quick ratio of 12.48 and a debt-to-equity ratio of 0.17. The company has a market cap of $862.05 million, a PE ratio of -9.29 and a beta of 0.98. The company’s 50 day moving average is $2.92 and its 200 day moving average is $2.42.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Tuesday, August 12th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). The company had revenue of $1.99 million during the quarter, compared to analysts’ expectations of $1.61 million. Taysha Gene Therapies had a negative return on equity of 78.44% and a negative net margin of 1,144.97%. On average, sell-side analysts forecast that Taysha Gene Therapies will post -0.35 EPS for the current year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.